To the editor:

Anti--glomerular basement membrane (anti-GBM) disease is a rare autoimmune small-vessel vasculitis.[@bib1] The recent confirmation of spatial and temporal clustering of cases suggests that environmental factors, including infection, may trigger disease in susceptible individuals.[@bib2]

Since the identification of the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), we have observed an unexpected number of new cases of anti-GBM disease presenting from our local population of approximately 2 million in North West London, UK. Between December 2019 and April 2020, a total of 8 new cases were diagnosed, a fivefold increase above the background rate of 1.5 per million per year ([Figure 1](#fig1){ref-type="fig"} ). These cases were typical of anti-GBM disease in their clinical features, autoimmune serology, histopathology, human leukocyte antigen associations, and outcomes ([Table 1](#tbl1){ref-type="table"} ).Figure 1**Incident cases, per 6 months, of anti--glomerular basement membrane (GBM) disease in North West London 2006--2020.** Between December 2019 and April (Apr) 2020, a total of 8 new cases of anti-GBM disease were diagnosed, giving an observed:expected case ratio of 5.64, based on disease incidence in the same population since November 2006. Applying a discrete Poisson temporal scan statistic over the period November 2006 to April 2020 confirmed a single significant disease cluster between December 2019 and April 2020 (*P* = 0.038). Statistical analysis was performed using SaTScan v9.6 (Martin Kulldorff and Information Management Services, Inc).Table 1Cases of anti-glomerular basement membrane disease presenting since December 2019Case12345678Age and gender45F69F27M63F72F34F73F37FEthnicitySouth AsianWhite BritishWhite BritishWhite BritishAfro-CaribbeanWhite BritishWhite BritishSouth AsianComorbidityRheumatic HDCOPDNoneBronchiectasisSLENoneHypertensionAsthmaSmoking statusNonsmokerEx-smokerNonsmokerNonsmokerNonsmokerNonsmokerEx-smokerNonsmokerHLA-DRDR12, DR15\
DR51, DR52DR11, DR15,\
DR51, DR52DR15,\
DR51DR4, DR15,\
DR51, DR53DR8, DR12,\
DR52DR4, DR15,\
DR51, DR53Not doneDR15, DR17,\
DR51, DR52Clinical presentation Antecedent infectionUTIURTI and diarrheal illnessLRTIDiarrheal illnessNoneURTINoneLRTI Prodrome duration5 wk1 wk7 wk3 wk2 wk8 wk1 wk2 wk Presenting symptomsLethargy, anorexia, visible hematuriaLethargy, anorexia, diarrhea, epistaxisNausea, vomiting, petechial rashLethargy, vomiting, diarrheaLethargy, anorexia, visible hematuriaLethargy, visible hematuriaLethargy, fever, dyspneaLethargy, dyspnea, visible hematuria Renal statusAKIAKI-RRTAKI-RRTAKI-RRTAKI-RRTAKIAKI-RRTAKI Alveolar hemorrhageNoNoNoNoNoNoNoNoLaboratory features Hemoglobin (g/l)7276678094886998 Platelets (x10^9^/l)23216712139128230396275 Creatinine (μmol/l)7272849403713871374258963222 C-reactive protein (mg/l)1051171341711641 Anti-GBM titre (iu/ml; normal \<6.9)12515852026231334593 ANCANegativeMPO-ANCANegativeMPO-ANCANegativeMPO-ANCANegativeNegative Renal biopsyCGN with linear IgGCGN with linear IgGNot doneCGN with linear IgGCGN with linear IgGCGN with linear IgGNot doneNot doneSARS-CoV-2 testing Viral PCR[a](#tbl1fna){ref-type="table-fn"}NegativeNegativeNegativeNegativeNegativeNot doneNot doneNot done Serum IgM[b](#tbl1fnb){ref-type="table-fn"}PositiveNegativeNegativeNegativePositiveNegativePositivePositive Serum IgG[b](#tbl1fnb){ref-type="table-fn"}NegativeNegativeNegativeNegativeNegativeNegativeNegativePositiveTreatment and outcome TreatmentPlasma exchange, cyclophosphamide, rituximab, corticosteroidsPlasma exchange, cyclophosphamide, rituximab, corticosteroidsNo immunotherapyPlasma exchange, cyclophosphamide, rituximab, corticosteroidsPlasma exchange, cyclophosphamide, rituximab, corticosteroidsPlasma exchange, cyclophosphamide, rituximab, corticosteroidsPlasma exchange, cyclophosphamide, rituximab, corticosteroidsPlasma exchange, cyclophosphamide, rituximab, corticosteroids Follow-up (d)9132137416183128 OutcomeIP treatment ongoingIP treatment ongoingReceiving OP hemodialysisRecovered kidney function, CKD VRecovered kidney function, CKD IVRecovered kidney functionReceiving OP hemodialysisRecovered kidney function Last creatinine (μmol/l)------ESKD42827476ESKD79[^1][^2][^3]

Prior to their presentation with anti-GBM disease, all patients reported nonspecific prodromal symptoms of 1--8 weeks duration. Five patients reported specific symptoms of respiratory tract infection and/or diarrheal illness during this period. At presentation with anti-GBM disease, 5 were tested for SARS-CoV-2 infection by viral RNA testing; none were positive. However, using serum samples stored at initial presentation, prior to immunosuppression and plasmapheresis, we detected circulating IgM and/or IgG antibodies to SARS-CoV-2 spike protein in 4 of 8 patients, suggesting recent infection and a potential role in the onset of anti-GBM disease in some cases. The detection of IgM and IgG antibodies to SARS-CoV-2, with negative testing for viral RNA, is in keeping with the hypothesis that the viral infection initiates an aberrant adaptive immune response targeting basement membrane that becomes clinically apparent days to weeks after the acute infection.

The first description of anti-GBM disease has been attributed to the American pathologist Ernest Goodpasture, who in 1919 (a century before the description of SARS-CoV-2) described a fatal pulmonary--renal syndrome that was considered secondary to an atypical influenza infection during the Spanish flu pandemic.[@bib3] We do not know if his patient had anti-GBM disease, although there have since been descriptions of anti-GBM disease outbreaks during influenza epidemics.[@bib4], [@bib5], [@bib6], [@bib7] The cases of anti-GBM disease reported here are the first to occur in association with SARS-CoV-2 infection, and although a causal relationship remains speculative, we highlight a novel cluster of anti-GBM disease, and the potential for viral infections to trigger secondary autoimmunity, including rapidly progressive forms of glomerulonephritis.
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[^1]: AKI, acute kidney injury; AKI-RRT, acute kidney injury requiring renal replacement therapy; ANCA, anti-neutrophil cytoplasm antibody; CGN, crescentic glomerulonephritis; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ESKD, end-stage kidney disease; F, female; GBM, glomerular basement membrane; HD, heart disease; HLA-DR, human leukocyte antigen--DR isotope; IP, inpatient; LRTI, lower respiratory tract infection; M, male; MPO, myeloperoxidase; OP, outpatient; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SLE, systemic lupus erythematosus; URTI, upper respiratory tract infection; UTI, urinary tract infection.

[^2]: Performed on Roche 6800 (Roche, Basel, Switzerland).

[^3]: Biomedomics lateral flow immunoassay.
